Alzheimer’s Association Statement on Lecanemab Phase 3 Full Results

CHICAGO, Nov. 29, 2022 /PRNewswire/ — The Alzheimer’s Association welcomes and is further encouraged by the full Phase 3 data presented by Eisai and Biogen from the CLARITY AD global Phase 3 clinical trial of lecanemab. The data presented today and published in the New England Journal of…

Click here to view original post